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Lower-extremity peripheral arterial occlusive disease
(PAD) identifies patients at high cardiovascular risk and is
an indicator of large-burden atherosclerosis. Platelet-inhib-
iting medications have been shown to significantly reduce
cardiovascular morbidity and mortality in high-risk pa-
tients.
Oral platelet inhibitors affect platelet function through
different mechanisms. Aspirin inhibits cyclooxygenase,
thereby reducing thromboxane A2 production. The ADP
receptor on the platelet membrane is blocked by the thien-
opyridines (ticlopodine and clopidogrel), and platelet cyclic
AMP phosphodiesterase is inhibited by cilostazol and dipy-
ridamole. The Antiplatelet Trialists’ Collaboration has
summarized the benefits of platelet inhibitors in patients at
high cardiovascular risk1,2 These studies have shown a
reduction in major ischemic events and death, and as a
result, aspirin has become a mainstay in the management of
these patients. More recently, the thienopyridine clopi-
dogrel was compared with aspirin in the CAPRIE (Clopi-
dogrel versus Aspirin in Patients at Risk of Ischemic
Events) trial, a large prospective, randomized study. The
results of CAPRIE demonstrated an 8.7% risk reduction of
major ischemic events in the clopidogrel-treated group
compared to aspirin.3 Subgroup analysis of the CAPRIE
trial demonstrated a greater relative risk reduction (23.9%)
of ischemic events in patients with PAD. The CAPRIE
results established the benefit of clopidogrel in patients
with peripheral arterial disease. The short- and long-term
benefit of combined platelet inhibition with aspirin and
clopidogrel in patients with cardiovascular diseases has
recently been documented in the CURE (Clopidogrel in
Unstable Angina to Prevent Recurrent Events) trial.4,5
The most common symptom of patients with PAD is
intermittent claudication. Cilostazol has been shown to
significantly improve walking distance and quality of life in
patients with intermittent claudication.6-8 Patients requir-
ing treatment with cilostazol may be simultaneously receiv-
ing other platelet inhibitors. This raises the issue of en-
hanced platelet inhibition by the combined presence of
multiple platelet inhibitors. Because multiple pathways of
platelet function are altered, there is a potential that addi-
tive or synergistic platelet inhibition may occur.
The template bleeding time is an in vivo measure of
overall platelet hemostatic function and can be used to
assess the effect of platelet inhibition.9 Platelet-inhibiting
drugs used for treatment of arterial disease prolong the
bleeding time. Determination of the effect on the bleeding
time remains a major component of the evaluation of any
new platelet-inhibiting drug. Despite a lack of evidence
correlating preoperative bleeding time to clinical bleed-
ing,10-12 this measurement provides valuable information
regarding the primary hemostasis mediated by platelets and
their interaction with the biologically active vessel wall. In
order to address the effect of platelet inhibitors, both singly
and in combination, in patients with peripheral arterial
disease, a prospective study was performed using the three
most commonly indicated medications in this patient pop-
ulation.
MATERIAL AND METHODS
Between June 2000 and March 2002, 26 patients were
evaluated for enrollment in this prospective study, and 21
were entered. The mean age of the patients was 65.9 
8.43 years with 71.4% males and 48% smokers. Twelve
(57%) were Caucasian and 43% African-American. Seven
patients (33.3%) were found to have diabetes insipidus.
Eligibility criteria included the presence of PAD causing
intermittent claudication, an ABI of less than 0.90, and no
contraindications to use of the study medications. The
subjects were required to have normal liver enzymes, pro-
thrombin, and partial thromboplastin times, and no history
of congestive heart failure or renal insufficiency.
The severity of lower-extremity occlusive disease was
classified by using the clinical categories of chronic limb
ischemia, as suggested by Rutherford et al.13 All patients
except one (n 25) in this study were classified as grade I,
which is characterized by the complaint of claudication.
One patient was grade II, defined as suffering from ische-
mic rest pain. Nine patients underwent further categoriza-
tion by treadmill testing. Six had results classifying them as
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category 2, two were category 1, and one patient was
category 3.
Five patients were found to be ineligible and were
dismissed after an initial screening visit. Reasons for ineli-
gibility included a lack of available venous access for re-
peated blood sampling (n 2), inability to comply with the
prolonged study period (n  2), and inability to discon-
tinue current platelet inhibition (n  1). One patient left
the study during the third visit, due to palpitations that
developed shortly after commencing cilostazol therapy.
Each patient underwent treatment with each possible
combination of aspirin (325 mg daily), clopidogrel (75 mg
daily), and cilostazol (100 mg twice a day). Initially, pa-
tients underwent a 14-day “washout” period, during which
all platelet inhibitors were discontinued. Patients then un-
derwent sequential treatment with every possible combina-
tion of these medications. Each phase was 14 days in
duration. Washout periods were used during the treatment
algorithm in order to avoid any carryover of the effect of
various treatments. The entire treatment program is dia-
grammed in Fig 1. This study was evaluated and approved
by the Institutional Review Board of the Temple University
Hospital, and all patients signed an approved informed
consent.
At the end of each treatment phase, patients were
examined by a physician. The bleeding time was measured
by using a standardized protocol. The bleeding times were
performed by 3 trained technicians, each of whom had
performed the test with acceptable results in at least 10
normal persons prior to beginning studies in the patients.
These technicians were not blinded to the study design or
to the patient treatment schedule. Under this protocol,
venous hypertension was established with a 40 mm Hg
venous tourniquet. A Surgicutt (International Technidyne
Corporation, Edison, NJ) automated scalpel was used to
make a 5-mm-long, 1-mm-deep horizontal incision located
1 cm below the antecubital crease. Filter paper (ITC) was
used to dab away excess blood every 30 seconds until no
blood was collected by the paper; at which time, the exam-
ination was deemed complete. A maximum of 20 minutes
was allowed for bleeding time determination. If the patient
continued to bleed at 20 minutes, the cuff was deflated,
pressure was applied, and the bleeding time was recorded as
20 minutes.
STATISTICAL METHODS
The dependent variable bleeding time was treated as a
continuous variable for all analyses. Means, standard devi-
ations, and number of observations were presented for each
variable. The experimental unit was each individual subject
(n  21). The experimental design was a single factor
repeated measures design. Prior to analysis, all data were
tested for normality by using the Shapiro-Wilk test. The
data were significantly non-normal for all variables. In order
to apply analysis of variance (ANOVA) methods, a “nor-
malized-rank” transformation was applied to the data. The
rank-transformed data was analyzed by using a mixed-
model ANOVA for repeated measures followed by multiple
comparisons to detect significant mean differences between
treatments. Multiple pair-wise comparisons used the
Dunn-Bonferroni adjustment to maintain an experiment-
wise type I error of 0.05 or less. Differences between means
were considered significant if the probability of chance
occurrence was 0.05 using two-tailed tests.
RESULTS
The results of bleeding time measurements are pre-
sented in Fig 2. The average baseline bleeding time for the
group was 4.29 minutes (SD, 1.69). Treatment with
cilostazol alone did not produce a significant change in
bleeding time (BT  5.41  2.69 minutes). Individual
treatment with either aspirin (BT 6.64 3.52, P .01)
or clopidogrel (BT  10.17  5.4, P  .01) caused a
significant increase in bleeding time over the baseline.
The effects of combination therapy varied among med-
ications. When cilostazol was added to either aspirin (ASA
 Cilo BT  8.3  4.27) or clopidogrel (Clop  Cilo BT
 12.7 7.46), no significant additional effect on bleeding
Fig 1. Outline of treatment program. Each treatment phase lasted for 14 days, with an initial washout period, during
which the patient took no platelet-inhibiting medications. Washout was repeated throughout the protocol as necessary
in order to prevent carryover of drug effects.
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time was noted. The combination of aspirin and clopi-
dogrel (BT  17.39  4.59) resulted in an increase in
bleeding time that was significant when compared with
treatment with either drug alone.
Triple therapy demonstrated a significant increase in
bleeding time when compared with the cilostazol-based
dual drug combinations (ASA  Clop  Cilo BT  17.92
 4.69, P .01 vs. ASACilo and ClopCilo) as well as
with each drug alone. When compared with aspirin plus
clopidogrel, the addition of cilostazol did not affect the
bleeding time.
DISCUSSION
With increasing understanding of cardiovascular risk,
and clinical experience with platelet inhibitors, it becomes
apparent that combined platelet inhibition with aspirin and
clopidogrel may be indicated for patients with PAD. This
subgroup of high-risk patients has been shown to signifi-
cantly benefit from clopidogrel compared with aspirin
alone.3 In the subset of PAD patients who have suffered
acute coronary ischemia, prolonged platelet inhibition with
aspirin and clopidogrel has been shown to be beneficial.4,5
In addition, prospective blinded trials are now underway to
compare combined platelet inhibition with monotherapy in
patients with PAD.
Our data demonstrate that aspirin has a significant
platelet-inhibiting effect compared with baseline values and
that clopidogrel has a greater effect than aspirin. The com-
bination of aspirin and clopidogrel significantly prolongs
bleeding time compared with either agent alone. A major
feature of this study is that these measurements were per-
formed in the same patients over the course of a prospective
treatment scheme, and each subject served as his or her own
control.
Aspirin and clopidogrel have previously demonstrated a
synergistic effect when used in combination. In an ex vivo
model, Moshfegh et al14 demonstrated that combining
aspirin and clopidogrel provided a significantly greater in-
hibition of ADP-mediated platelet aggregation than either
drug alone. Studies in animals have demonstrated that
combined platelet inhibition with aspirin and clopidogrel is
more effective than are single agents in reducing thrombus
weight in an ex vivo model of stent thrombosis.15,16
Many patients with PAD have symptoms of intermit-
tent claudication and require treatment with cilostazol. The
bleeding time after treatment with cilostazol alone is not
significantly different from the baseline. Cilostazol added
to either aspirin or clopidogrel does not alter the bleeding
time compared with either agent alone. Furthermore, when
cilostazol is added to the combination of aspirin and clopi-
dogrel, no additional effect is observed.
Although this is a small trial, it is focused on the effect
of oral platelet inhibitors on the bleeding time in patients
with lower-extremity PAD. The sequence of administration
of study drugs was specifically designed so that triple-drug
therapy was the final study segment. As such, the study
drugs were not randomized, which could add potential bias
to our observations, although we believe that this is un-
likely.
Numerous laboratory tests have been designed to eval-
uate various aspects of platelet function. These include
assessment of platelet function in vitro by using platelet
aggregometry, the platelet function analyzer (PFA-100),
and other methods to specifically evaluate platelet re-
sponses, such as platelet secretion or signaling events. We
chose the bleeding time as the end point for this study as it
reflects a readily available clinical measure of platelet hemo-
static function and has been extensively used to evaluate the
Fig 2. Average bleeding time for each treatment phase. Error bars demonstrate SE. Base, Baseline BT; ASA, aspirin
325 mg QD; Clop, clopidogrel 75 mg QD; Cilo, cilostazol, 100 mg BID. *P  .05 versus baseline. **P  .05 versus
all single agents and versus ASA  Cilo and Clop  Cilo.
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effect of all platelet-inhibiting drugs. Although prior stud-
ies have failed to specifically link bleeding time results to
perioperative bleeding complications,10-12 the number of
confounding variables associated with such observations
probably masks the true association. The CURE investiga-
tors reported more major bleeding complications with
combined platelet inhibition using aspirin plus clopidogrel
than with aspirin alone.4 As observed here, the combina-
tion of aspirin plus clopidogrel provided a significantly
greater bleeding time than did either of these agents alone,
any other single agent, or any other dual combination. We
believe that there is likely to be a clinically relevant link
between our observations of the bleeding time effect of
combined platelet inhibitors and the increased bleeding
complications observed in the CURE trial.
Our data suggest that cilostazol is a relatively weak
platelet inhibitor compared to aspirin and clopidogrel.
Combining cilostazol with aspirin or clopidogrel does not
alter the bleeding time compared with either agent alone.
Although the combination of aspirin and clopidogrel has a
significant added effect on bleeding time compared with
either agent alone, the addition of cilostazol to this combi-
nation does not appear to alter platelet function. These
results suggest that when combined platelet inhibition with
aspirin and clopidogrel is indicated because of cardiovascu-
lar risk, bleeding time is prolonged, which is consistent with
the clinical results noted in randomized trials. However,
when cilostazol is required because of symptoms of inter-
mittent claudication, it can be added without additional
perturbation in platelet function as reflected by the bleed-
ing time.
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